Yuvezzi (carbachol/brimonidine tartrate ophthalmic solution) is now commercially available in the US for presbyopia treatment

A fixed-dose combination of carbachol and brimonidine tartrate ophthalmic solution (Yuvezzi; Visus Therapeutics, Inc) is now available in the United States for the treatment of presbyopia in adults, following FDA approval. The once-daily topical therapy represents a pharmacologic option to improve near visual acuity through a pupil-modulating mechanism, adding to a small but growing class of presbyopia-correcting eye drops.

Presbyopia is a near-universal, age-related condition characterized by progressive loss of accommodation, typically manifesting after age 40 to 45 years. It affects an estimated 128 million individuals in the United States and approximately 2 billion globally, with functional consequences that include difficulty reading and performing near tasks under varying lighting conditions.¹^-³ Until recently, management has relied largely on optical correction (eg, reading glasses, multifocal lenses) or surgical approaches, underscoring ongoing interest in pharmacologic alternatives.

Regulatory and clinical overview

The FDA approval of carbachol/brimonidine ophthalmic solution was based on data from phase 3 clinical trials evaluating the efficacy and safety of the combination in improving near vision in presbyopic adults. Publicly available details on the pivotal trials remain limited at the time of writing, and peer-reviewed publications describing the full study data sets could not be independently verified. According to the sponsor, the therapy demonstrated improvement in near visual acuity with a duration of effect compatible with once-daily dosing.

The formulation combines 2 pharmacologic agents: carbachol, a direct-acting cholinergic agonist, and brimonidine tartrate, an α-2 adrenergic receptor agonist. The proposed mechanism involves induction of miosis to create a “pinhole effect,” increasing depth of focus and thereby improving near vision.⁴ Carbachol stimulates contraction of the iris sphincter and ciliary muscle, while brimonidine inhibits the iris dilator muscle, potentially enhancing and prolonging the miotic response.

Although detailed safety data have not been fully disclosed in the press release, prior experience with miotic agents and α-2 agonists suggests potential adverse effects, including headache, dim vision under low-light conditions, conjunctival hyperemia, and, less commonly, systemic adrenergic effects.⁵^,⁶ Careful patient selection and counseling may be required, particularly in individuals with preexisting ocular or systemic comorbidities.

Clinical context and treatment landscape

The approval and availability of this dual-agent therapy expands a nascent category of pharmacologic treatments for presbyopia. The first FDA-approved presbyopia eye drop, pilocarpine 1.25% (Vuity; Allergan/AbbVie Inc), demonstrated that miotic therapy could transiently improve near vision without corrective lenses.⁵ However, limitations, including duration of effect, tolerability, and variability in response, have prompted continued development of alternative agents and combinations.

Compared with pilocarpine monotherapy, the addition of brimonidine in the current formulation may offer theoretical advantages in modulating pupil size more selectively and potentially prolonging the duration of action. However, without head-to-head comparative trials or peer-reviewed phase 3 data, it is unclear whether these pharmacodynamic differences translate into clinically meaningful improvements in efficacy or tolerability.

From a practical standpoint, pharmacologic presbyopia therapies may be most suitable for patients seeking spectacle independence for intermittent near tasks, rather than continuous correction. Clinicians should also consider factors such as baseline pupil size, lighting conditions, occupational needs, and tolerance for potential side effects when discussing treatment options.

Drug background and development

Carbachol has long been used in ophthalmology for intraoperative miosis and glaucoma management, while brimonidine is widely prescribed for lowering intraocular pressure in patients with glaucoma or ocular hypertension.⁶ The combination of these agents for presbyopia reflects a repurposing strategy aimed at leveraging complementary mechanisms of action.

The development of combination miotic therapies aligns with broader efforts to optimize pharmacologic presbyopia correction by balancing efficacy, duration, and tolerability. Several investigational agents, including other cholinergic combinations and lens-softening therapies, remain under study.⁷

Interpretation and remaining questions

While the availability of carbachol/brimonidine ophthalmic solution provides an additional option for presbyopia management, its place in therapy will depend on real-world effectiveness, patient adherence, and tolerability. The absence of publicly available, peer-reviewed phase 3 data limits independent assessment of the magnitude and durability of benefit.

Key unanswered questions include the consistency of response across age groups and refractive profiles, long-term safety with chronic use, and comparative performance against existing therapies. Postmarketing surveillance and future publications will be important in clarifying these issues.

Limitations and next steps

The current report relies in part on sponsor-provided information and has limited access to independently verified clinical trial data. Clinicians should interpret efficacy and safety claims cautiously pending publication of full trial results. Additional studies, including comparative and real-world analyses, will be important to define the clinical utility of this therapy.

References

1. Fricke TR, Tahhan N, Resnikoff S, et al. Global prevalence of presbyopia and vision impairment from uncorrected presbyopia. Ophthalmology. 2018;125(10):1492-1499. doi:10.1016/j.ophtha.2018.04.013

2. Holden BA, Fricke TR, Ho SM, et al. Global vision impairment due to uncorrected presbyopia. Arch Ophthalmol. 2008;126(12):1731-1739. doi:10.1001/archopht.126.12.1731

3. United Nations Population Division. United Nations. Accessed April 7, 2026. https://www.un.org/development/desa/pd/

4. Abdelkader A. Improved presbyopic vision with miotics. Eye Contact Lens. 2015;41(5):323-327. doi:10.1097/ICL.0000000000000137

5. US Food and Drug Administration approves VUITY™ (pilocarpine HCI ophthalmic solution) 1.25%, the first and only eye drop to treat presbyopia (age-related blurry near vision). Abbvie. October 29, 2021. Accessed April 7, 2026. https://news.abbvie.com/2021-10-29-U-S-Food-and-Drug-Administration-Approves-VUITY-TM-pilocarpine-HCI-ophthalmic-solution-1-25-,-the-First-and-Only-Eye-Drop-to-Treat-Presbyopia-Age-Related-Blurry-Near-Vision

6. Oh DJ, Chen JL, Vajaranant TS, Dikopf MS. Brimonidine tartrate for the treatment of glaucoma. Expert Opin Pharmacother. 2019;20(1):115-122. doi:10.1080/14656566.2018.1544241

7. Grzybowski A, Kapitanovaite L, Zemaitiene R. An updated systematic review of pharmacological treatments for presbyopia. Adv Ophthalmol Pract Res. 2024;4(4):220–225. doi:10.1016/j.aopr.2024.09.001